TB-PRACTECAL:评估含贝达喹啉和普托马尼方案治疗成人耐多药肺结核安全性与疗效的随机对照开放标签II-III期试验研究方案
TB-PRACTECAL是一项开放标签、随机对照、II/III期非劣效性试验,在乌兹别克斯坦、南非和白俄罗斯开展,评估含贝达喹啉和普托马尼的24周方案治疗利福平耐药肺结核的安全性与疗效。研究分两阶段,主要结局为随机化后72周不利结局百分比。试验因疗效经数据安全监查委员会建议提前终止。
要点
- 全球每年约46万人患利福平耐药结核病,现行推荐方案疗程9-24个月,疗效差且毒性显著。
- 研究纳入15岁及以上需新疗程的利福平耐药肺结核患者,不论HIV状态。
- 试验因疗效经数据安全监查委员会建议提前终止,将报告招募结束前数据及招募结束后72周计划最终分析。
核心结论
- 含贝达喹啉和普托马尼的24周方案治疗利福平耐药肺结核的安全性与疗效正在评估中,试验因疗效经数据安全监查委员会建议提前终止。
研究设计与样本
- TB-PRACTECAL为开放标签、随机对照、II/III期非劣效性试验,在乌兹别克斯坦、南非和白俄罗斯开展。
- 纳入15岁及以上需新疗程的利福平耐药肺结核患者,不论HIV状态。
- 第一阶段相当于IIB期试验,患者按研究中心分层随机分配至四种方案之一。
- 研究方案含口服贝达喹啉、普托马尼和利奈唑胺,其中两个方案分别 additionally 含莫西沙星(第1臂)和氯法齐明(第2臂)。
- 研究臂治疗在直接观察下给药24周,标准治疗臂为36至96周。
主要发现
- 全球利福平耐药结核病每年影响约46万人。
- 目前推荐方案疗程9-24个月,疗效差且携带显著毒性。
- 试验因疗效经数据安全监查委员会建议提前终止。
关键数值与推荐
- 主要结局为随机化后72周不利结局百分比,复合早期治疗中断、治疗失败、复发、失访和死亡。
- 研究臂治疗在直接观察下给药24周,标准治疗臂为36至96周。
局限性
- 试验实施面临COVID-19大流行的重大挑战。
- 试验因疗效经数据安全监查委员会建议提前终止,将报告招募结束前收集的数据及招募结束后72周的计划最终分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and more efficacious regimen would improve outcomes for people with rifampicin-resistant tuberculosis. METHODS: TB-PRACTECAL is an open-label, randomised, controlled, phase II/III non-inferiority trial evaluating the safety and efficacy of 24-week regimens containing bedaquiline and pretomanid to treat rifampicin-resistant tuberculosis. Conducted in Uzbekistan, South Africa and Belarus, patients aged 15 and above with rifampicin-resistant pulmonary tuberculosis and requiring a new course of therapy were eligible for inclusion irrespective of HIV status. In the first stage, equivalent to a phase IIB trial, patients were randomly assigned one of four regimens, stratified by site. Investigational regimens include oral bedaquiline, pretomanid and linezolid. Additionally, two of the regimens also included moxifloxacin (arm 1) and clofazimine (arm 2) respectively. Treatment was administered under direct observation for 24 weeks in investigational arms and 36 to 96 weeks in the standard of care arm. The second stage of the study was equivalent to a phase III trial, investigating the safety and efficacy of the most promising regimen/s. The primary outcome was the percentage of unfavourable outcomes at 72 weeks post-randomisation. This was a composite of early treatment discontinuation, treatment failure, recurrence, lost-to-follow-up and death. The study is being conducted in accordance with ICH-GCP and full ethical approval was obtained from Médecins sans Frontières ethical review board, London School of Hygiene and Tropical Medicine ethical review board as well as ERBs and regulatory authorities at each site. DISCUSSION: TB-PRACTECAL is an ambitious trial using adaptive design to accelerate regimen assessment and bring novel treatments that are effective and safe to patients quicker. The trial took a patient-centred approach, adapting to best practice guidelines throughout recruitment. The implementation faced significant challenges from the COVID-19 pandemic. The trial was terminated early for efficacy on the advice of the DSMB and will report on data collected up to the end of recruitment and, additionally, the planned final analysis at 72 weeks after the end of recruitment. TRIAL REGISTRATION: Clinicaltrials.gov NCT02589782. Registered on 28 October 2015.
引用
- Berry C, du Cros P, Fielding K, et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials. 2022. PMID: 35698158. doi:10.1186/s13063-022-06331-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。